Clinical burden and health service challenges of chronic heart failure

European Journal of Heart Failure, Supplement

Volumn 8, Issue SUPPL. 1, 2009, Pages

  Hobbs, F D R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DIAGNOSTIC ACCURACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH SERVICE; HEART FAILURE; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; THORAX RADIOGRAPHY;

EID: 77956565690     PISSN: 15674215     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp011     Document Type: Short Survey

References (61)

1. Alam M, Rosenhamer G, Hogland C. Compatibility of echocardiography and chest X-ray following myocardial infarction. J Intern Med 1989; 226: 771-773.
2. American College of Cardiology/American Heart Association. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart failure). Circulation 1995; 92: 2764-2784.
3. Anonymous. Failure to treat heart failure (editorial). Lancet 1992; 339: 278-279.
4. Badgett RG, Mulrow CD, Otto PM, Ramirez G. How well can the chest radio-graph diagnose left ventricular dysfunction?J Gen Intern Med 1996; 11: 625-634.
5. Badgett RG, Lucey LR, Murlow CD. Can clinical examination diagnose left-sided heart failure in adults. JAMA 1997; 277: 1712-1719.
6. Bundkirchen A, Schwinger RHG. Epidemiology and economic burden ofchronic heart failure. Eur Heart J 2004; 6 (Suppl D): D57-D60.
7. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II. Lancet 1999; 353: 9-13.
8. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994; 71: 584-587.
9. Clarke KW, Gray D, Hampton JR. How common is heart failure? Evidence from PACT (prescribing analysis and cost) data in Nottingham. J Publ Health Med 1995; 17: 459-464.
10. Cleland JGF, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999; 1: 229-241.
11. Cleland JGF, Swedberg K, Follath F et al. The EuroHeartFailure survey programme-a survey on the quality ofcare among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003a; 24: 442-463.
12. Cleland JGF, Cohen-Solal A, Cosin Aguilar J et al. Management of heart failure in primarycare (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2003b; 360: 1631-1641.
13. Cline CM, Willenheimer RB, Erhardt LR, Wiklund I, Israelsonn BY. Health related quality of life in elderly patients with heart failure. Scand Cardiovasc J 1999; 33: 278-285.
14. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
15. Cowie MR, Wood DA, Coats A et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J 1999; 20: 421-428.
16. Davie AP, Francis CM, Love MP et al. Value of an electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312: 222.
17. Davies MK, Hobbs FDR, Davis RC et al. Prevalence of left ventricular systolic dysfunction and heart failure in the general population: main findings from the ECHOES (Echocardiographic Heart of England Screening) Study. Lancet 2001; 358: 439-445.
18. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
19. Domanski MJ. Beta-Blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 2000; 35 Suppl A: 202A.
20. Eriksson H. Heart failure: agrowing public health problem. J Intern Med 1995; 237: 135-141.
21. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-1456.
22. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J 1993; 126: 1042-1047.
23. Havranek EP, Ware MG, Lowes BD. Prevalence of depression in congestive heart failure. Am J Cardiol 1999; 84:348-350.
24. Ho KKL, Pinsky JL, Kannel WB. The epidemiology of heart failure: The Framingham Study. J Am Cardiol 1993a; 22 (Supp A): 6A-13A
25. Ho KKL, Anderson KM, Kannel WB et al. Survival after the onset of congestive heartfailure in Framingham HeartStudySubjects. Circulation 1993b;88: 107-115.
26. Hobbs FDR, Davis RC, McLeod S et al. Prevalence of heart failure in 'high risk' groups. J Am Coll Cardiol 1998; 31: S5-85C.
27. Hobbs FDR, Jones MI, Allan TS et al. European survey of primary care physician perceptions and practice in heart failure diagnosis and management (Euro-HF study). Eur Heart J 2000; 21: 1877-1887.
28. Hobbs FDR, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002; 324: 1498-1502.
29. Hobbs FDR, Roalfe AK, Davis RC, Hare R, Davies MK. Reliability of N-terminal proBNP (NT-proBNP) assay in diagnosing left ventricular systolic dysfunction within representative and high-risk populations. Heart 2004; 90: 866-870.
30. Hobbs FDR, Roalfe AK, Davis RC, Davies MK, Hare R. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007; 28: 1128-1134.
31. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update forthe Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society Circulation 2005; 112: e154-e235.
32. J Am Coll Cardiol 2005; 46: e1-e82.
33. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
34. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Beta-blockers in heart failure: meta-analysis of randomized trials. Circulation 1998; 98: 1184-1191.
35. McDonagh TA, Morrison CE, Lawrence A et al. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-833.
36. McDonagh TA, Cunningham AD, Morrison CE et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86: 21-26.
37. McKee PA, Castelli WP, McNamara PM, Kannell WB. The natural history of heart failure: The Framingham Study. N Engl J Med 1971; 285: 1441-1446.
38. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalisation for heart failure in Scotland 1980-1990. Eur Heart J 1993; 14: 1158-1162.
39. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
40. Morgan S, Smith H, Simpson I et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ 1999; 318: 368-372.
41. Murberg TA, Bru E, Svebak S, Tveteras R, Aarsland T. Depressed mood and subjective health symptoms as predictors of mortality in patients with congestive heart failure: a two-year follow-up study. Int J Psychiatry Med 1999; 29: 311-326.
42. O'Connell JB, Bristow MR. Economic impactof heartfailure in the United States: time for a different approach. J Heart Lung Transplant 1994;13 (Suppl 4): S107-S112.
43. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
44. Parameshwar J, Shackell MM, Richardson A, Poole-Wilson PA, Sutton GC. Prevalence of heart failure in three general practices in North West London. Br J Gen Pract 1992; 42: 287-289.
45. Pfeffer MA, Braunwald E, Moye LA et al. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.
46. Pfeffer MA, Swedberg K, Granger CB et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766. (Pubitemid 37093915)
47. Pitt B, White H, Nicolau J, Martinez F et al. EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46: 425-431.
48. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
49. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315-321.
50. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190-1195.
51. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-306.
52. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
53. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection frac-tions. N Engl J Med 1992; 327: 685-691.
54. Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of patients with chronic conditions. Results from the medical outcomes study. JAMA 1989; 262: 907-913. (Pubitemid 19208947)
55. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJV. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315-322.
56. Sutton GC. Epidemiological aspects of heart failure. Am Heart J 1990; 120: 1538-1540.
57. Swedberg K, Cleland J, Dargie H et al.; Task Force for the Diagnosis and Treat-ment ofChronic Heart Failure of the European Society ofCardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140.
58. The NETWORK Investigators: Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998;19: 481-489.
59. Troughton R, Frampton C, Yandle T, Espine E, Nicholls M, Richards A. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
60. Weeldon NM, McDonald TM, Fluker CJ, McKendrick AD, McDevitt DG, Struthers AD. Echocardiography in chronic heart failure in the community. Q J Med 1993; 86: 17-20.
61. Willenheimer R, Erhardt L, Cline C, Rydberg E, Israelsson B. Exercise training in heart failure improves quality of life and exercise capacity. Eur Heart J 1998; 19: 774-781.